|
|
FierceBiotech
May 1
Comment
AbbVie ($ABBV) and InterMune ($ITMN) may have won at least a temporary reprieve in their fight to stop the EMA from releasing trial data on their drugs. But the powerful agency is vowing to battle it out in court as they insist that the pharma...
StreetInsider.com
Apr 24
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/InterMune%2C+Inc.+%28ITMN%29+Tops+Q1+EPS+by+9c/8275871.html for the full story.
Forbes
Apr 22
Comment
InterMune (ITMN) reports its first quarter earnings on Wednesday, April 24, 2013.
Market Intelligence Center
Apr 15
Comment
InterMune (NASDAQ: ITMN) closed Friday's trading session at $9.61. In the past year, the stock has hit a 52-week low of $7.21 and 52-week high of $12.77. InterMune (ITMN) stock has been showing support around $8.92 and resistance in the $9.98...
StreetInsider.com
Mar 21
Comment
InterMune Inc. (NASDAQ: ITMN) 10% HIGHER; Esbrie receives positive final appraisal Determination from NICE for Idiopathic Pulmonary Fibrosis (IPF)
Cleveland BioLabs (NASDAQ: CBLI) 9% HIGHER; Cantor Fitzgerald initiates coverage on with a Buy. PT...
Benzinga
Mar 21
Comment
InterMune (NASDAQ: ITMN) reported Wednesday that the National Institute for Health and Clinical Excellence (NICE), the health technology appraisal body in England and Wales, has issued its Final Appraisal Determination (FAD) recommending Esbriet®...
Benzinga
Feb 22
Comment
Stifel Nicolaus maintained InterMune (NASDAQ: ITMN) with a Buy rating and lowered the price target from $19.00 to $17.00.
Stifel Nicolaus commented, "Although European regulatory/reimbursement headwinds will likely prevail near-term, we...
FierceBiotech
Feb 20
Comment
As a pioneer in the fibrosis field, InterMune ($ITMN) has often been at the center of considerable buyout buzz. In the spring of 2011, for instance, the company had to pour cold water on fevered speculation that a deal was in the making after its...
Forbes
Feb 15
Comment
InterMune (ITMN) is expected to book a wider loss than a year ago when it reports fourth quarter earnings on Thursday, February 21, 2013 with analysts expecting a loss of 86 cents per share, down from a loss of 69 cents per share a year ago.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
